Latest news for Halberd (OTC:HALB) Stock

Halberd Corp is a research-based biotechnology company seeking to discover and develop medical treatments for a range of diseases. The Company's extracorporeal treatment is designed to treat hard-to-cure blood-borne, neurologic and infectious diseases. The Company's patented methodology removes the appropriate bodily fluid from the patient, in a continuous fashion, like dialysis, or in a batch process, like blood sample testing.

News

Movers & Shakers

Intraday Update

Markets

Movers

Trading Ideas

General

AACAY

AAWW

ABBV

ABMD

ACGBF

ACRGF

ADMP

AERI

AGTK

AIBGY

ALKM

ALNA

ALSWF

AMAG

ANGI

APGMF

APNHY

APOP

ARCH

ARLO

ARLP

ARREF

ASRT

Alterity Therapeutics Limited - American Depositary Shares

ATHE

ATHOF

ATRA

ATVK

AVNS

AWLCF

AXGN

AXVEF

AZRX

AZZUF

BAFYY

BBCP

BBVA

BBVXF

BCDA

BCEFF

BCEL

BCYC

BDVSY

BEDU

BFIN

BHKLY

BICEF

BIDU

BIOAF

BIREF

BJRI

BKKLY

BKRIF

BKRIY

BLCM

BLMN

BLRX

BNDSF

BNEFF

BPAQF

BPFH

BRKMY

BRTX

BrightSphere Investment Group plc Ordinary Shares

BSIG

BTHE

BUDZ

BWFG

BXEFF

BZLFY

CADE

CAIXY

CAKE

CALX

CARB

CARCY

CARG

CARS

Stocks That Fell Through 52-Week Lows Wednesday

Halberd Corp

Halberd signs revenue sharing agreement with Athena GTX

HALB

Press Releases

Halberd Corporation 2023 Year-End CEO Update and 2024 Goals

Halberd's Top Executives Join Forces with Athena GTX CEO Mark Darrah Unveiling 2024 Powerful Partnership Outlook on "The Street Reports Podcast"

Halberd and Mississippi State University to Commence Stage II Advanced TBI Nasal Spray Testing

12 OTC Stocks to Watch: Clean Vision Corporation (OTCQB: CLNV), NaturalShrimp Inc (OTCQB: SHMP), Northwest Biotherapeutics, Inc. (OTCQB: NWBO), and More

Stocks Under 1¢ to Watch Now! SPZI, HALB, DPLS, RSHN, ALST, ZRFY

Halberd's Patented Drug, LDN+, the Subject of a Limited Clinical Trial Under an Innovative Four-Company Cooperative Research and Development (CRADA) Contract

Halberd's Patented LDN+ Drug Has Begun Pre-Pilot Trials With Military Veterans

Halberd's Traumatic Brain Injury Treatment Projects Align with New U.S. House Bill

Halberd/Athena GTX Research Promises a Much Brighter Future

Health Care

Halberd Corp's (OTC: HALB) Groundbreaking Traumatic Brain Injury (TBI) Mitigation Nasal Spray Shows Promising Phase II Initial Test Results

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

Comments

Halberd

News

Latest news for Halberd (OTC:HALB) Stock

Wednesday, August 07, 2019